These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32221804)

  • 1. Structure-Based Immunogenicity Prediction of Uricase from Fungal (Aspergillus flavus), Bacterial (Bacillus subtillis) and Mammalian Sources Using Immunoinformatic Approach.
    Tripathi S; Parmar J; Kumar A
    Protein J; 2020 Apr; 39(2):133-144. PubMed ID: 32221804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
    Nyborg AC; Ward C; Zacco A; Chacko B; Grinberg L; Geoghegan JC; Bean R; Wendeler M; Bartnik F; O'Connor E; Gruia F; Iyer V; Feng H; Roy V; Berge M; Miner JN; Wilson DM; Zhou D; Nicholson S; Wilker C; Wu CY; Wilson S; Jermutus L; Wu H; Owen DA; Osbourn J; Coats S; Baca M
    PLoS One; 2016; 11(12):e0167935. PubMed ID: 28002433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
    Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
    Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new practical system for evaluating the pharmacological properties of uricase as a potential drug for hyperuricemia.
    Feng J; Li X; Yang X; Zhang C; Yuan Y; Pu J; Zhao Y; Xie Y; Yuan H; Bu Y; Liao F
    Arch Pharm Res; 2010 Nov; 33(11):1761-9. PubMed ID: 21116779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing intein-mediated protein cleaving for purification of uricase, a multimeric enzyme.
    Alishah K; Asad S; Khajeh K; Akbari N
    Enzyme Microb Technol; 2016 Nov; 93-94():92-98. PubMed ID: 27702489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
    Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
    J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Elucidation of a Urate Oxidase from
    Chiu YC; Hsu TS; Huang CY; Hsu CH
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein.
    Tong M; Wang S; Luan J; Xie Q; Wang L; Shen X; Xiong S
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):131989. PubMed ID: 38697425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperuricemia and gout: new insights into pathogenesis and treatment.
    Pillinger MH; Rosenthal P; Abeles AM
    Bull NYU Hosp Jt Dis; 2007; 65(3):215-21. PubMed ID: 17922673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative structural modeling and docking studies of uricase: possible implication in enzyme supplementation therapy for hyperuricemic disorders.
    Beedkar SD; Khobragade CN; Bodade RG; Vinchurkar AS
    Comput Biol Med; 2012 Jun; 42(6):657-66. PubMed ID: 22537975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
    Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
    PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A widely distributed gene cluster compensates for uricase loss in hominids.
    Liu Y; Jarman JB; Low YS; Augustijn HE; Huang S; Chen H; DeFeo ME; Sekiba K; Hou BH; Meng X; Weakley AM; Cabrera AV; Zhou Z; van Wezel G; Medema MH; Ganesan C; Pao AC; Gombar S; Dodd D
    Cell; 2023 Aug; 186(16):3400-3413.e20. PubMed ID: 37541197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of modification of a bacterial uricase with N-hydroxysuccinimide esters of succinate and carbonate of monomethoxyl poly(ethylene glycol).
    Zhang C; Yang X; Gao A; Hu X; Pu J; Liu H; Feng J; Liao J; Li Y; Liao F
    Biotechnol Appl Biochem; 2014; 61(6):683-90. PubMed ID: 24512141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutionary history and metabolic insights of ancient mammalian uricases.
    Kratzer JT; Lanaspa MA; Murphy MN; Cicerchi C; Graves CL; Tipton PA; Ortlund EA; Johnson RJ; Gaucher EA
    Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3763-8. PubMed ID: 24550457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
    Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
    J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
    Bomalaski JS; Clark MA
    Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia.
    Xiong H; Zhou Y; Zhou Q; He D; Deng X; Sun Q; Zhang J
    Nanomedicine; 2016 Aug; 12(6):1557-66. PubMed ID: 27013130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice.
    Tran L; Das S; Zhao L; Finn MG; Gaucher EA
    Biomacromolecules; 2023 May; 24(5):2003-2008. PubMed ID: 37126604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.